A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood

[1]  A. Blann,et al.  Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[3]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[4]  D. Ross,et al.  Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Hudis,et al.  Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Jain,et al.  Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[8]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[10]  C. Heeschen,et al.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.

[11]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[12]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[13]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.